Education
About Us
Working with TipRanks
Follow Us
Spero Therapeutics Inc (SPRO)
NASDAQ:SPRO
SPRO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.73 - $1.81
Previous CloseN/A
Volume61.58K
Average Volume (3M)99.39K
Market Cap
$46.89M
Enterprise Value$859.32K
Total Cash (Recent Filing)$34.08M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)10.8
Beta1.26
Next Earnings
May 09, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding54,518,166
10 Day Avg. Volume107,249
30 Day Avg. Volume99,386
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)N/A
Price to Sales (P/S)0.42
Price to Cash Flow (P/CF)0.90
P/FCF Ratio0.90
Enterprise Value/Market Cap0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda-0.88
Forecast
1Y Price Target
$5.00Price Target Upside481.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Spero Therapeutics News
PremiumCompany Announcements
Spero Therapeutics Reports 2024 Financial Results and Updates
PremiumCompany Announcements
Spero Therapeutics Faces SEC Probe and Leadership Changes
---
Bulls Say, Bears Say
Bulls Say
FDA Approval PotentialThe PIVOT-PO trial of tebipenem HBr could potentially lead to FDA approval for complicated urinary tract infections, supported by persuasive results and prior studies.
Financial StabilitySpero Therapeutics has sufficient financial resources to fund its operations and capital expenditures into mid-2026, providing a stable financial outlook.
Partnership And Milestone PaymentsSpero's partner GlaxoSmithKline plc is slated to pay up to $400M in potential milestone and royalty payments related to tebipenem HBr.
Bears Say
Clinical Trial SetbacksThe Phase 2a proof-of-concept study of SPR720 did not meet its primary endpoint, leading to the suspension of its development program.
Operational RestructuringSpero Therapeutics plans a restructuring and reduction in force of approximately 39% to support other developments.
Regulatory ChallengesSpero responded to a 'Wells Notice' from the staff of the Boston Regional Office of the U.S. Securities and Exchange Commission regarding its preliminary determination to recommend a civil enforcement action or administrative proceeding against Spero.
---
Ownership Overview
7.88% Insiders
4.35% Mutual Funds
18.07% Other Institutional Investors
66.31% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SPRO FAQ
What was Spero Therapeutics Inc’s price range in the past 12 months?
Spero Therapeutics Inc lowest stock price was $0.73 and its highest was $1.81 in the past 12 months.
What is Spero Therapeutics Inc’s market cap?
Spero Therapeutics Inc’s market cap is $46.89M.
When is Spero Therapeutics Inc’s upcoming earnings report date?
Spero Therapeutics Inc’s upcoming earnings report date is May 09, 2025 which is in 42 days.
How were Spero Therapeutics Inc’s earnings last quarter?
Spero Therapeutics Inc released its earnings results on Mar 27, 2025. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.31 by -$0.07.
Is Spero Therapeutics Inc overvalued?
According to Wall Street analysts Spero Therapeutics Inc’s price is currently Undervalued.
Does Spero Therapeutics Inc pay dividends?
Spero Therapeutics Inc does not currently pay dividends.
What is Spero Therapeutics Inc’s EPS estimate?
Spero Therapeutics Inc’s EPS estimate is -0.27.
How many shares outstanding does Spero Therapeutics Inc have?
Spero Therapeutics Inc has 54,518,166 shares outstanding.
What happened to Spero Therapeutics Inc’s price movement after its last earnings report?
Spero Therapeutics Inc reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.31. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Spero Therapeutics Inc?
Currently, no hedge funds are holding shares in SPRO
---
Spero Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (481.40% Upside)
$5.00 (481.40% Upside)
Blogger Sentiment
Bullish
SPRO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 22.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $235.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.85%
12-Months-Change
Fundamentals
Return on Equity
5.90%
Trailing 12-Months
Asset Growth
26.20%
Trailing 12-Months
Company Description
Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
---
SPRO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Spero Therapeutics is advancing its tebipenem HBr program with promising potential and strategic partnerships, but faces challenges with its SPR720 trial results and financial performance, including decreased revenue and increased losses.Read More>---
SPRO Stock 12 Month Forecast
Average Price Target
$5.00
▲(481.40% Upside)
Technical Analysis
Best Analysts Covering SPRO
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-20.98%
reiterated a buy rating 2 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -20.98% per trade.
---